Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D

Chemistry and Biology

Volumn 4, Issue 4, 1997, Pages 297-307

  Kick, Ellen K ^a   Roe, Diana C ^b   Skillman, A Geoffrey ^b   Liu, Guangcheng ^a   Ewing, Todd J A ^b   Sun, Yaxiong ^b   Kuntz, Irwin D ^b   Ellman, Jonathan A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aspartyl proteases; cathepsin D; combinatorial chemistry; structure based design

Indexed keywords

EID: 0031127997     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(97)90073-9     Document Type: Article

References (38)

1. Kuntz, I.D. (1992). Structure-based strategies for drug design and discovery. Science 257, 1078-1082.
2. Kuntz, I.D., Meng, E.C. & Shoichet, B.K. (1994). Structure-based molecular design. Accts. Chem. Res. 27, 117-123.
3. Thompson, L.A. & Ellman, J.A. (1996). Synthesis and applications of small molecule libraries. Chem. Rev. 96, 555-600.
4. Gordon, E.M., Barrett, R.W., Dower, W.J., Fodor, S.P.A. & Gallop, M.A. (1994). Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. J. Med. Chem. 37, 1385-1401.
5. Cohen, N.C., Blaney, J.M., Humblet, C., Gund, P. & Barry, D.C. (1990). Molecular modeling software and methods for medicinal chemistry. J. Med. Chem. 33, 883-894.
6. Gallop, M.A., Barrett, R.W., Dower, W.J., Fodor, S.P.A. & Gordon, E.M. (1994). Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J. Med. Chem. 37, 1233-1251.
7. Terrett, N.K., et al., & Steele, J. (1995). The combinatorial synthesis of a 30,752-compound library: discovery of SAR around the endothelin antagonist, FR-139,317. Bioorg. Med. Chem. Lett. 5, 917-922.
8. Martin, E.J., Blaney, J.M., Siani, M.A., Spellmeyer, D.C., Wong, A.K. & Moos, W.H. (1995). Measuring diversity: experimental design of combinatorial libraries for drug discovery. J. Med. Chem. 38, 1431-1436.
9. Takahashki, K. (1995). Aspartic Proteinases Structure, Function, Biology, and Biomedical Implications. Plenum Press, New York, USA.
10. Adams, J. & Stein, R. (1996). Novel inhibitors of the proteasome and their therapeutic use in inflammation. Ann. Rep. Med. Chem. 31, 279-288.
11. Edmunds, J.J., Rapundalo, S.T. & Siddiqui, M.A. (1996). Thrombin and factor Xa inhibition. Ann. Rep. Med. Chem. 31, 51-60.
12. Miller, D.K. (1996). Regulation of apoptosis by members of the ICE family and the Bcl-2 family. Ann. Rep. Med. Chem. 31, 249-268.
13. Lam, P.Y.S., et al., & Erickson-Viitanen, S. (1994). Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263, 380-384.
14. DeCamp, D., Ogden, R., Kuntz, I. & Craik, C. (1996). Site-Directed Drug Design. In Site-Directed Drug Design, (Cleland, J.L. & Craik, C.S., eds), pp. 467-505, Wiley-Liss, New York, USA.
15. Westley, B.R. & May, F.E.B. (1996). Cathepsin D and breast cancer. Eur. J. Cancer 32, 15-24.
16. Ladror, U.S., Snyder, S.W., Wang, G.T., Holzman, T.F. & Krafft, G.A. (1994). Cleavage at the amino and carboxyl termini of Alzheimers amyloid-beta by cathepsin D. J. Biol. Chem. 269, 18422-18428.
17. Cataldo, A.M., Hamilton, D.J., Barnett, J.L., Paskevich, P.A. & Nixon, R.A. (1996). Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J. Neurosci. 16, 186-199.
18. Whitesitt, C.A., et al., & Panetta, J.A. (1996). Synthesis and structure-activity relationships of benzophenone as inhibitors of cathepsin D. Bioorg. Med. Chem. Lett. 6, 2157-2162.
19. Wiley, R.A. & Rich, D.H. (1993). Peptidomimetics derived from natural products. Med. Res. Rev. 13, 327-384.
20. Baldwin, E.T., et al., & Erickson, J.W. (1993). Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc. Natl Acad. Sci. U.S.A. 90, 6796-6800.
21. Jupp, R.A., et al., & J. Kay (1990). The selectivity of statine-based inhibitors against various human aspartic proteinases. Biochem. J. 265, 871-878.
22. Agarwal, N.S. & Rich, D.H. (1986). Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin. J. Med. Chem. 29, 2519-2524.
23. Kick, E.K. & Ellman, J.A. (1995). Expedient method for the solid-phase synthesis of aspartic acid protease inhibitors directed toward the generation of libraries. J. Med. Chem. 38, 1427-1430.
24. Lewis, R.A., et al., & Kuntz, I.D. (1992). Automated site-directed drug design using molecular lattices. J. Mol. Graphics 10, 66-78.
25. Roe, D.C. & Kuntz, I.D. (1995). BUILDER v2: improving the chemistry of a de novo design strategy. J. Comput. Aided Mol. Des. 9, 269-282.
26. Roe, D.C. (1995). Application and Development of Tools for Structure-based Drug Design. University of California, San Francisco, USA.
27. Jarvis, R.A. & Patrick, E.A. (1973). Clustering using a similarity measure based on shared near neighbors. IEEE Comput. C22, 1025-1034.
28. Willett, P., Winterman, V. & Bawden, D. (1986). Implementation of non-hierarchical cluster-analysis methods in chemical information systems: selection of compounds for biological testing and clustering of substructure search output. J. Chem. Inf. Comput. Sci. 26, 109-118.
29. Willett, P. (1987). Similarity and Clustering in Chemical Information Systems. John Wiley & Sons, New York, USA.
30. Krafft, G.A. & Wang, G.T. (1994). Synthetic approaches to continuous assays of retroviral proteases. Methods Enzymol. 241, 70-86.
31. Schecter, I. & Berger, A. (1968). On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162.
32. Weiner, S.J., et al., & Weiner, P.A. (1984). A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 106, 765-784.
33. Gasteiger, J. & Marsili, M. (1980). Iterative partial equalization of orbital electronegativity: rapid access to atomic charges. Tetrahedron Lett. 36, 3219.
34. Gasteiger, J. & Marsili, M. (1981). Prediction of proton magnetic resonance shifts: the dependence on hydrogen charges obtained by iterative partial equalization of orbital electronegativity. Organ. Magn. Reson. 15, 353-360.
35. Gschwend, D.A. & Kuntz, I.D. (1996). Orientational sampling and rigid-body minimization in molecular docking, revisited: on-the-fly optimization and degeneracy removal. J. Comput-Aided Drug Des. 10, 123-132.
36. Meng, E.C., Shoichet, B.K. & Kuntz, I.D. (1992). Automated docking with grid-based energy evaluation. J. Comput. Chem. 13, 505-524.
37. Romesburg, H.C. (1984). Cluster Analysis For Researchers. Lifetime Learning Publications, Belmont, CA, USA.
38. Cha, S., Agarwal, R.P. & Parks, J. (1975). Tight-binding inhibitors-II: non-steady state nature of inhibition of mild xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. Biochem. Pharmacol. 24, 2187-2197.